Combining the mutually exclusive KRAS and BRAF mutations, a highly significant association was observed with 68% A-type patients harbored an activating BRAF or KRAS mutation (Supporting Information Table S2 ).
← all excerpts
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.
1
—
—